A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.
Swiecicki PL, et al. Among authors: jackson tl.
Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.
Invest New Drugs. 2016.
PMID: 27225873
Free PMC article.
Clinical Trial.